BioCentury
ARTICLE | Politics, Policy & Law

Alliance for Regenerative Medicine sees advanced therapies as pilot for EU's regular use of real-world evidence

July 29, 2020 3:00 PM UTC

As the European Commisson hammers out how best to incorporate real world evidence into the future of medicines regulation and reimbursement, the Alliance for Regenerative Medicine is calling for the EU bloc to use cell and gene therapies as a testing ground for the best ways to build and use a pan-European real-world evidence infrastructure.

On Wednesday the Alliance for Regenerative Medicine (ARM) published a position paper that says if the EU wants to maintain its leadership in the development and reimbursement of advanced therapy medicinal products (ATMPs), it should create a roadmap for how European healthcare centers can adopt common standards and data requirements for the collection and use of real-world evidence (RWE)...